Loading clinical trials...

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents: A Randomized Controlled Trial

NCT07339956•China-Japan Friendship Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to evaluate the clinical efficacy and safety of YiWei Jiaohuang Ointment in treating gastrointestinal bleeding associated with oral antithrombotic therapy. The main question it aims to answer is: Does Yiwei JiaoHuang Ointment accelerate the conversion to negative results in fecal occult blood tests among patients with gastrointestinal bleeding associated with antithrombotic therapy? Researchers will compare use rabeprazole alone as routine therapy to see if Yiwei JiaoHuang Ointment can accelerate the conversion to negative results in fecal occult blood tests. Participants will ： Take Yiwei JiaoHuang Ointment every day for 2 weeks. Return to the hospital for a fecal occult blood test after 3 days, 1 week, and 2 weeks of medication.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Oral therapy with at least one antiplatelet or anticoagulant agent, including: aspirin, clopidogrel, ticagrelor, prasugrel, warfarin, rivaroxaban, apixaban, edoxaban, dabigatran, etc.;
•BARC stage 1 or 2;
•Traditional Chinese Medicine pattern identified as phlegm-heat and blood stasis obstruction syndrome;
•Age 18-90 years;
•Signed informed consent.

Exclusion Criteria

•Patients with gastrointestinal bleeding resulting in hemoglobin levels \<20 g/L and/or requiring hospitalization;
•Gastrointestinal malignancies;
•Cases where the source of occult blood cannot be distinguished, such as fresh bleeding from hemorrhoids;
•Concurrent use of hemostatic traditional Chinese medicine preparations like Yunnan Baiyao;
•Significant liver or kidney dysfunction, with ALT, AST, or serum creatinine exceeding three times the upper limit of normal;
•Pregnant women, women planning pregnancy, or lactating women;
•Individuals deemed unsuitable for this clinical trial by the investigator.

Locations (1)

China-Japan Friendship Hospital

Beijing, China

Key Dates

Start Date

January 10, 2026

Primary Completion Date

August 1, 2026

Completion Date

August 30, 2026

Last Updated

January 26, 2026

Enrollment

ESTIMATED participants

Conditions

Gastrointestinal Bleeding

Interventions

A Chinese herb formula--Yiwei Jiaohuang Onitment

DRUG

Rabeprazole Enteric-Coated Tablets

DRUG

Contacts

Jie Zhang

CONTACT

+86 15652385971 zhangjie9496@bucm.edu.cn

Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants

NCT07333144

Gastrointestinal Bleeding

View study

RECRUITING

The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper GI Bleeding

NCT07261228

Carbon Footprint in Upper GI EndoscopyDyspepsia+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 26, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Yiwei Jiaohuang Ointment for Gastrointestinal Bleeding Associated With Oral Antithrombotic Agents

Inclusion Criteria

Exclusion Criteria

Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants

The Difference in Carbon Footprint Between Diagnostic Upper GI Endoscopy in Dyspeptic Patients Versus Therapeutic Upper GI Bleeding

Gastrointestinal Bleeding and Atmospheric Pressure Relationship

Australian and New Zealand Massive Transfusion Registry

Urgent Panendoscopy in Patients Presenting With Hematochezia

Usefulness of Metoclopramide to Improve Endoscopic Visualization in Upper Gastrointestinal Bleeding